In the present study, we observed that MM patients who responded to the treatment had higher abundances of effector/cytotoxic cells, including T cells expressing higher levels of CD57 and/or CD45RA and NK cells with CD57, CD16, and CD56 (NCAM), in comparison to patients who did not respond. The gene discussed is NCAM1; the disease is Miyoshi myopathy.